Pathology informatics selected abstracts
April 2026—Technical considerations during validation of Genius digital diagnostic system; Applicability of accreditation requirements to machine learning-based methods in molecular oncology testing
Webinars and Commercial Conversations — Register Now
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, December 1, 2026, 1 PM-2 PM ET
Join UCSF clinical microbiologists as they share their journey from using multiple respiratory testing platforms to implementing a flexible, stewardship-driven testing strategy. Learn how customizable respiratory panels helped streamline workflows, improve efficiency, and better align testing with patient needs.
Webinar presenters Danielle Ingebrigtsen, MHS, Clinical Laboratory Scientist Supervisor, UCSF Health, and Rama Yakubu, MD, PhD, Assistant Professor of Laboratory Medicine, Co-Director of Microbiology, UCSF Health.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diasorin.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Abstracts
Clinical pathology selected abstracts
March 2026—Continuous glucose monitoring is recommended for type 1 and type 2 diabetes patients, particularly those using insulin.
Anatomic pathology selected abstracts
March 2026—A study developed an AI-based system, ATLS-8, to quantify CD8+ tumor-infiltrating lymphocytes and assess their prognostic value in hepatocellular carcinoma patients undergoing liver resection.
Molecular pathology selected abstracts
March 2026—A study at UPHS and MGB found racial and socioeconomic disparities in access to genetic evaluation.
Clinical pathology selected abstracts
February 2026—A study of 42 thrombocytopenic neonates found that platelet transfusions increased platelet counts but did not significantly impact bleeding. Another study investigated the impact of probiotics on gut microbiota after colonoscopy.
Anatomic pathology selected abstracts
February 2026—A study introduced a computational framework to analyze collagen disorder architectural (CoDA) features in colon cancer patients, revealing significant associations with clinical, molecular, and genetic factors. Additionally, a dedicated histopathologic assessment of rituximab-associated CVID-like enteropathy highlighted key histologic features, emphasizing the importance of pathologist awareness of this entity.
Molecular pathology selected abstracts
February 2026—A study of 830 children with pediatric central nervous system tumors found that 23.3% carried germline pathogenic variants in cancer predisposition genes, impacting tumor development and outcomes. Another study identified pathogenic variants in 13.2% of infertile women experiencing IVF/ICSI failures, with TUBB8 being the most frequently mutated gene.
Clinical pathology selected abstracts
January 2026—Federally qualified health centers (FQHCs) in Illinois demonstrated higher guideline adherence for kidney disease testing compared to non-FQHCs. Patients with low eGFR or diabetes at FQHCs were more likely to receive recommended uACR and dual testing, respectively.
Anatomic pathology selected abstracts
January 2026—Ossifying fibromyxoid tumors with lipomatous and cartilaginous differentiation are rare mesenchymal neoplasms that can be challenging to diagnose. A study identified six cases with these features, expanding the tumor’s known histomorphological spectrum.
Pathology informatics selected abstracts
January 2025—TITAN, a multimodal whole slide foundation model, outperforms existing slide encoders in various diagnostic and prognostic tasks, including rare disease classification. While promising, TITAN’s limitations, such as partial image representation and domain shift, necessitate further validation and workflow integration before clinical use.